Search

Boehringer Ingelheim, Sodexo and Food Rescue US Collaborate to Nourish Fairfield County’s Food Insecure in Response to the COVID-19 Crisis

Boehringer Ingelheim Launches External Innovation Hub in China

Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches

Life forward - Boehringer Ingelheim unveils its evolved company brand

Taking patient centricity to new heights

Learn about how we focus on putting patients first and finding solutions to meet their healthcare needs.

BI to Donate 75k Rabies Vaccine Doses | Boehringer Ingelheim US

Boehringer Ingelheim to donate 75,000 doses of IMRAB® vaccine to the Global Alliance for Rabies Control through shots for Good Initiative.

Combating The Rise of Heartworm Disease in Dogs | Boehringer Ingelheim US

Click to read more on the Boehringer Ingelheim initiative to combat the rising incidence rates of heartworm disease in dogs by over half a million.

200 employees make a difference with record-breaking volunteer efforts

Helping pets in hurricane-ravaged Puerto Rico

A Few Ways We Support US Livestock | Boehringer Ingelheim US

Click here to view the Boehringer Ingelheim infographic on how we support livestock across the USA in partnership with the USDA's agriculture department.

Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic

Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies

Baseball Legend Bernie Williams Calls on the Public to Join Queen Latifah, The Bacon Brothers, Paul Shaffer, as Judges of the Breathless® Ballad Challenge

Boehringer Ingelheim to unveil oncology research at WCLC

Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio

Our Purpose

Why we exist

Boehringer Shows Support for Children with Skin Conditions

This year, Boehringer Ingelheim joined campers at Camp Discovery in Millville, PA to demonstrate its support for those facing chronic skin conditions.

Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease

Intensive education about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines

The findings demonstrate the benefit of clinic-level educational interventions

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical

Top-line Phase II Data for treatment of MASH

Boehringer Ingelheim and Zealand Pharma announced top-line Phase II data for treatment of metabolic dysfuntion-associated steatohepatitis (MASH).

US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction

FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis

Expert insights: top online lung cancer questions answered

As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.

Final analysis of the observational GioTag study: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small cell lung cancer

Our Ambition 2025

What we want to achieve

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers